Viatris (NASDAQ: VTRS) — 2Q26 Earnings Preview

Timing correction: Viatris is scheduled to report today, Thursday, August 6, 2026, not tomorrow. The company’s earnings call is scheduled for 8:30 a.m. ET.

Preview takeaway

Viatris enters 2Q26 with a relatively constructive setup: the company delivered a clean 1Q beat-like operating performance, reaffirmed full-year guidance, and has several near-term pipeline and launch catalysts that can reinforce the narrative that it is becoming a more durable growth-and-cash-flow company rather than a declining legacy-generics business.

The tradeoff is that expectations and the stock have moved. VTRS closed at $17.67 on August 5, up roughly 42% year to date, after jumping about 9% following its May 7 first-quarter report. A merely in-line quarter and another guidance reiteration may therefore be insufficient; investors will likely focus on whether the strong 1Q growth drivers held through 2Q, whether management raises its outlook, and whether recent regulatory milestones support the 2027 growth algorithm.

What matters most

1. Can Greater China remain a meaningful growth engine?

Greater China was the major upside contributor in 1Q:

Sales grew 18% operationally year over year, ahead of management’s prior expectations.
Growth reflected favorable cardiovascular demand, commercial investment, and more than doubling of e-commerce sales.
Management increased its full-year regional expectation to mid- to high-single-digit operational growth from low single digits.

For 2Q, investors should look for evidence that the regional strength remains broad-based rather than a one-quarter surge. Continued double-digit growth would support a potential full-year outlook increase; a pronounced deceleration would reinforce the concern that policy, pricing, or channel dynamics can make the China result less durable.

Key question for the call: Did China sustain growth above the revised mid/high-single-digit full-year planning assumption, and how much visibility does management have into the second half?

2. Is North American generics momentum offsetting pressure elsewhere?

In 1Q, North America grew 3%, driven by estradiol demand, Breyna, and contributions from complex-generic launches. That helped counter softer trends in several other areas:

Europe: roughly 1% decline, affected by softer markets, Dymista competition, and supply constraints.
Emerging Markets: flat operationally, as established-brand growth was offset by lower-margin ARV supply constraints.
JANZ: down roughly 2%, due to Australia competition and Japanese price regulation, though management cited favorable performance in products including Creon and Amitiza.

The central question is whether VTRS can sustain positive base-business growth outside China. This matters because the long-term plan calls for approximately 4% organic growth by 2030; the 1Q operational-growth result of 3% was an encouraging start, but the company needs broader consistency to support that trajectory.

3. The bar for guidance is rising

Viatris reaffirmed 2026 guidance after 1Q:

2026 guidance	Range	Midpoint
Total revenue	$14.45B–$14.95B	$14.70B
Adjusted EBITDA	$4.15B–$4.45B	$4.30B
Adjusted EPS	$2.33–$2.47	$2.40
FCF, excluding transaction/restructuring costs	$1.95B–$2.35B	$2.15B

Management stated that revenue, adjusted EBITDA, and adjusted EPS should be approximately 52% weighted to the second half. Applying that phasing mechanically to the guidance midpoint, and subtracting reported 1Q results, implies a rough 2Q framework of:

Illustrative 2Q26 midpoint implied by full-year guide and stated phasing*	Approximate level
Revenue	$3.54B
Adjusted EBITDA	$1.01B
Adjusted EPS	$0.56

*This is an analytical estimate, not company guidance or published consensus. It assumes guidance is unchanged and that the stated 52% second-half weighting applies approximately to each metric.

That setup suggests a 2Q quarter broadly similar to 1Q in absolute terms: 1Q revenue was $3.52B, adjusted EBITDA was $1.05B, and adjusted EPS was $0.59. A raise would likely require continued China outperformance, stable North American generics, and no incremental supply, competitive, or FX headwinds.

Margin and cost-savings execution

The first quarter showed the operating leverage investors have wanted to see:

Revenue grew 3% operationally.
Adjusted EBITDA grew 10% operationally.
Adjusted gross margin held at 56%.
Adjusted SG&A fell to 22% of revenue, from 24% in the prior-year quarter.

Management attributed part of the benefit to disciplined cost control, strategic-review savings, and expense phasing. The company is targeting roughly $400 million of net savings under its enterprise-wide strategic review, with approximately 30% expected in 2026.

The risk is that part of the 1Q cost performance was timing-related. Investors should distinguish between:

Structural savings that can support margins into 2027–28; and
Temporary favorable phasing that reverses as launch, commercial, and R&D investment ramps later in the year.

Free cash flow, capital allocation, and balance-sheet developments

Cash generation remains a key part of the VTRS thesis. Management expects more than $2.5 billion of cash available for deployment in 2026, while guiding to $1.95B–$2.35B of free cash flow excluding transaction and restructuring costs.

1Q free cash flow was $348M on a reported basis, or $459M excluding transaction and restructuring costs. Management expects free cash flow to be materially stronger in the second half because of working-capital timing and lower one-time cash costs.

Balance-sheet execution should also be in focus:

At March 31, Viatris had $1.8B of cash, approximately $14.3B of total debt, including current maturities.
In June, the company issued €650M of 4.25% senior notes due 2033, using proceeds principally to refinance its $1.675B of 3.95% notes due in 2026.
In July, it entered a new ¥40B term-loan agreement.

These actions appear directed at refinancing and liquidity management rather than a change in capital-allocation strategy. Still, investors will want updated commentary on leverage, interest expense, buybacks, the dividend, and the size and timing of any business-development deployment.

Pipeline and catalyst watch

The 2Q call could be more important for portfolio catalysts than for the quarter itself.

Near-term items

Xulane Lo: The low-dose estrogen weekly contraceptive patch had a stated FDA PDUFA goal date of July 30, 2026. Viatris had not separately disclosed an outcome in the materials reviewed ahead of earnings, making an update a potentially important event-day item.
Fast-acting meloxicam: Management expected an FDA decision in the second half of 2026 and has emphasized its expectation for opioid-sparing label language. The commercial plan involves a targeted specialty sales force of roughly 150–200 representatives and positions the asset as a 2027 growth driver.
Phentolamine ophthalmic solution for presbyopia: Assigned PDUFA date of October 17, 2026.
Japan: Following March approval of Effexor for generalized anxiety disorder, investors are awaiting decisions for pitolisant in excessive daytime sleepiness/narcolepsy and progress on Nefecon in IgA nephropathy.

Longer-dated value drivers

Cenerimod: Phase III OPUS-1 and OPUS-2 trials in systemic lupus erythematosus are fully enrolled, with results expected in the first half of 2027.
Selatogrel: Enrollment in the SOS-AMI Phase III study was running near 1,200 patients per month; full enrollment was targeted by year-end 2026.
Generic GLP-1s: Management frames this as a longer-term opportunity, more relevant to the 2030-and-beyond period than near-term estimates, with a particular U.S. focus on device and auto-injector capabilities.

Risks heading into the print

China normalization or policy risk. China is now a more important swing factor after driving 1Q upside.
Generic competition and price erosion. VTRS still has meaningful exposure to mature products, Dymista pressure, developed-market generics competition, and loss-of-exclusivity dynamics.
ARV and manufacturing supply constraints. Management said it had included known ARV disruption risks in its outlook, but resolution timing matters for Emerging Markets performance and working capital.
Cash-flow timing. Strong second-half cash flow is part of the full-year setup; any delay in working-capital normalization or incremental restructuring cash outlays could temper confidence.
Pipeline/regulatory execution. With the shares stronger, investors may increasingly value the probability, label quality, and launch potential of Xulane Lo and fast-acting meloxicam—not simply their approval status.
No guidance raise. Given the strong 1Q result and favorable share-price performance, an unchanged guide without compelling second-half commentary could be received less favorably than it would have been three months ago.

What would constitute a bullish versus cautious outcome?

Bullish

Revenue and adjusted EBITDA ahead of the implied 2Q run rate.
Sustained strong Greater China growth and healthy North American generics performance.
A guidance increase, or at least a clear indication that management sees upside to the current range.
Confirmation of structural—not merely timing-related—cost savings.
Favorable regulatory/launch commentary on Xulane Lo and fast-acting meloxicam.
Reaffirmed confidence in second-half free-cash-flow conversion and balanced shareholder returns/M&A capacity.

Cautious

China growth slows sharply, or management flags new policy/channel uncertainty.
Generic pricing, Europe, ARVs, or manufacturing constraints become larger offsets.
EBITDA performance relies materially on delayed spending rather than lasting productivity gains.
Free-cash-flow expectations are pushed later or reduced.
Guidance remains unchanged but management’s tone becomes more guarded.
Regulatory updates are delayed, unfavorable, or less commercially attractive than investors expect.

Bottom line

Viatris has shifted toward a more credible growth-and-execution story: 1Q showed revenue growth, operating leverage, and a path to substantial cash generation. The 2Q report must now validate that the first-quarter momentum was repeatable—particularly in Greater China and North American generics—and show that management can convert base-business stability, cost savings, and a broad set of regulatory milestones into a stronger 2027 outlook.